Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb,

Slides:



Advertisements
Similar presentations
Introduction to Existing State Disclosure Laws and Regulations Summit on Disclosure, Transparency and Aggregate Spend For Drug, Device and Biotech Companies.
Advertisements

Pharmaceutical Compliance Congress June 9, 2003 HHS OIG Guidance: Key Risk Areas John T. Bentivoglio Arnold & Porter Copyright, Arnold & Porter,
Professional Education Support Wyeth Pharmaceuticals Melinda Somasekhar, PhD.
PwC Medical Device Compliance Survey Discussion of Survey Results.
Pharmaceutical and Medical Device Manufacturer Conduct Melissa J. Lopes, Deputy General Counsel Massachusetts Department of Public Health.
Pharmacy Benefit Managers (PBMs)
Continuing Professional Development Conflict of Interest This presentation has been developed by the COI Working Group to assist in the implementation.
© 2009 Cengage Learning. All Rights Reserved. Healthcare Fraud and Abuse.
MSRB Proposed Rules and Interpretations NALHFA 2011 Annual Educational Conference May 20, 2011.
Marketing to Doctors – Payments for Loyalty Julie Brill Assistant Attorney General Vermont Attorney General ’ s Office Montpelier,
Pharmaceutical Compliance Congress: “State of the States” October 27, 2008 Janice G. Cunningham Jeffrey L. Handwerker.
Sales & Marketing Compliance Training
Medicare Parts C and D Fraud, Waste, and Abuse Compliance Training
Compliance Requirements for the Pharmaceutical Industry and Impact on Marketing Practices Timothy M. Cunniff, Pharm.D. Vice President, Global Regulatory.
Fraud, Waste & Abuse DEFICIT REDUCTION ACT OF 2005 Presented by: MARCH Vision Care, 2013.
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Compliance Best Practices in a Post Orthopedic Environment David Matyas.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
© 2009 The McGraw-Hill Companies, Inc. All rights reserved. 1 McGraw-Hill Chapter 5 HIPAA Enforcement HIPAA for Allied Health Careers.
Medicare Advantage & Part D Compliance Training 2009.
Implementation of Disclosure Legislation in Massachusetts National Disclosure Summit March 6, 2009 Allan Coukell, Director of Policy.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
OIG COMPLIANCE GUIDANCE FOR PHYSICIAN PRACTICES Washington County Hospital Association, Inc. CME Program October 26, 2000.
© 2008 Foley Hoag LLP. All Rights Reserved. 1 The New Massachusetts Pharmaceutical & Medical Device Marketing Regulations How to Address and Overcome Likely.
Blue Cross of Idaho Medicare Advantage Provider Fraud, Waste and Abuse Training Fall 2009.
How to Develop Internal Monitoring Programs SEVENTH ANNUAL PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS AND BEST PRACTICES FORUM Stephen F. Mohr Global.
Pitfalls and Lessons Learned: Advanced Implementation Strategies for a Compliant Grant Process National CME Audioconference December 9, 2008.
1 Strategies for a Compliant Grant Process CIA Monitoring Obligations A. Monica Jonhart Director-U S Pharmaceuticals Compliance Bristol-Myers Squibb.
Sales and Marketing in the Pharmaceutical Industry: At the Vortex of the Perfect Legal Storm Paul E. Kalb, M.D., J.D. Princeton, N.J. - June 7, 2004.
1 Implementing the OIG Final Guidance for Pharma An audioconference co-sponsored by FDAnews and the Health Care Compliance Association Joseph W. Metro,
Pharmaceutical Compliance Congress Washington, DC June 9, 2003 The HHS OIG Guidance: An In-Depth Analysis of Risk Areas Panelists: Patrick Davish, Merck.
1 Investigating Fraud & Abuse Violations in Medical Research Janet Rehnquist, Esq. Venable LLP th Street, NW Washington, DC
+ Conflict of Interest in Physician-Industry Relationships.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
KEY ENFORCEMENT ISSUES - The Government's Perspective Kathleen Meriwether Assistant United States Attorney Eastern District of Pennsylvania UNITED STATES.
The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.
Pharmaceutical Regulatory and Compliance Congress Special Pre-Conference Workshop: HHS OIG Model Compliance Guidance November 13, 2002.
+ Role of Industry in Clinical Care, Research, and Education.
Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.
When Pharmaceutical Marketing Crosses the Line: Best Practices For Investigation and Remediation.
1 Continuing Medical Education and Industry Sponsorship The Pharma, Biotech and Device Colloquium Princeton, NJ June 7, 2005 Julie K. Taitsman, M.D., J.D.
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
Pwc Fifth Annual National Congress on Health Care Compliance Pharmaceutical Sales and Marketing: Are You Afraid to Look Under the Rocks? Michael P. Swiatocha.
Session 1.01 US Healthcare Professionals Abroad – Issues and Practical Solutions Caroline West – Senior VP, Chief Compliance and Risk Officer Shire Pharmaceuticals.
1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.
Welcome General Compliance Training.  To inform you who to contact to ask questions  To let you know that you are responsible to disclose  To share.
ROPES & GRAY LLP The Compliance Environment and Grant Process: Oversight and Response in the Pharmaceutical Industry Howard L. Dorfman December 9, 2008.
1 Pharmacy Management and Cost-Containment: Pharmaceutical Fraud Investigations, Prosecutions and Compliance Strategies John T. Bentivoglio
The Physician Payments Sunshine Act Legislation Ann Leopold Kaplan October 27, 2008.
California’s New Compliance Law Kelly N. Reeves
Building A Pharmaceutical Compliance Program Presentation to the Sixth Annual Congress on Health Care Compliance February 7, 2003 Janice Toran Fujisawa.
Overview of Huron and the International Medical Device Compliance Code Compendium The Second Annual Medical Device Regulatory, Reimbursement and Compliance.
Enforcement Trends in the Pharmaceutical Industry Lewis Morris Chief Counsel Office of Inspector General, DHHS.
Slide 1 Pharmaceutical Compliance Congress 2003 November 12-14, 2003 Kickbacks, False Claims, and Risk Areas: A Primer for Pharmaceutical and Biotechnology.
Pharmacy Benefit Management (PBM) 101
The Growing Role of HHS-IG/DOJ, & Whistleblowers, In Drug Marketing Policy John F. Kamp August 25, 2005.
Compliance and Enforcement Roundtable Discussion
National Pharma Audioconference Revised PhRMA Code: Key Provisions
Action Items: Monitoring Off-Label Promotion Do’s and Don’t’s
Tamara V. Scoville, Esq. Reed Smith LLP
Complying with FDA/OIG Rules
Analysis of the Proposed Sunshine Rule: Legal Considerations
A Short History of Pricing Related Fraud and Abuse Issues 8th Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Washington,
Health Care Fraud Investigations
Brussels, June 6, 2007 Paul E. Kalb, M.D., J.D.
California’s “Comprehensive Compliance Program” Law
“Netting” Prices Pharmaceutical Compliance Congress November 15, 2004
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
Implementing Controls Around Grants, Consulting Agreements, CME, Preceptorships, and Other Promotional Practices Paul E. Kalb Heidi C. Chen Fourth Annual.
Presentation transcript:

Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb, M.D., J.D. Sidley Austin Brown & Wood LLP (202)

S IDLEY A USTIN B ROWN & W OOD LLP 2 Manufacturers are Under Intense Scrutiny Prior to the late ‘90s manufacturers received relatively little attention Do not generally submit “claims” Drug pricing very complex Surge of interest in late ‘90s Manufacturers allegedly “influence” government reimbursement through AWP, Direct Price Manufacturer relationships with purchasers and prescribers

S IDLEY A USTIN B ROWN & W OOD LLP 3 The TAP Settlement September 2001 $875 million total $585 million Civil penalties $290 million Criminal penalties Issues Free samples Grants AWP spread

S IDLEY A USTIN B ROWN & W OOD LLP 4 Activities Under Scrutiny Excessive reimbursement “Marketing the spread” Bundled goods Grants Nominal pricing “Private labeling” Grants Administrative fees Gifts, “business courtesies” Samples AWP Medicaid rebates “Kickbacks”

S IDLEY A USTIN B ROWN & W OOD LLP 5 Role of Customers? Complicit? Anti-kickback statute is bilateral: prohibits both the giving and receiving of improper remuneration TAP physicians Caremark physicians Aiding and abetting false claims Whistleblowers? Qui Tam relator can be anyone Recipient of TAP grant Ven-A-Care

S IDLEY A USTIN B ROWN & W OOD LLP 6 Industry Self-Regulation: The PhRMA Code Developed by PhRMA Effective July 1, 2002 Voluntary guidance

S IDLEY A USTIN B ROWN & W OOD LLP 7 Highlights of The PhRMA Code No entertainment or recreational events Occasional meals allowed in conjunction with presentations, but must be modest and in appropriate venue Manufacturers may directly support CME and other third- party scientific and educational programs so long as independent Manufacturers may retain consultants Written contract Pre-identified, “legitimate” need Appropriate selection criteria Reasonable number of consultants Records of work Venue and circumstances of meetings must be conducive to consultant work; social events must be “clearly subordinate”

S IDLEY A USTIN B ROWN & W OOD LLP 8 Highlights of The PhRMA Code (cont’d) Manufacturers may support speaker bureaus Extensive training Valuable service Participants must meet criteria for consultants Manufacturers may support attendance at educational conferences by medical students, residents and fellows if selected by institution Manufacturers may provide: Items for the benefit of patients Practice-related items of de minimis value

S IDLEY A USTIN B ROWN & W OOD LLP 9 OIG Draft Compliance Program Guidance Compliance officer Compliance committee Policies and procedures Training Regular compliance audits Standard Procedural Recommendations

S IDLEY A USTIN B ROWN & W OOD LLP 10 OIG Draft Compliance Program Guidance (cont’d) “Risk Areas”  Integrity of data  Inducements Relationships with purchasers  Discounts  AWP Relationships with physicians and other health care professionals  Direct and indirect “switching”  Gifts and other gratuities  PhRMA Code as “minimum” standard Relationships with sales agents  Samples

S IDLEY A USTIN B ROWN & W OOD LLP 11 The Customer Perspective Your Perspective Depends on Where You Sit “RECOMMENDER” PRESCRIBER PURCHASER

S IDLEY A USTIN B ROWN & W OOD LLP 12 The Purchaser Perspective Discounts: Are they safe-harbored? If not, is the arrangement nonetheless legal? Special issues re: bundling Special issues re: “market share” arrangements AWP spread Other “remuneration” FMV for services rendered? Grants for legitimate scientific or educational purposes? Are “grants” really “price terms”?

S IDLEY A USTIN B ROWN & W OOD LLP 13 The “Recommender” Perspective (PBMs, HMOs, Pharmacies, Consultants) AKS prohibits payments “to recommend or arrange for” Can’t mean what it says: The First Amendment OIG concerns: “Switching” “White coat marketing” Key issues: Disclosure? Truthful/non-deceptive?

S IDLEY A USTIN B ROWN & W OOD LLP 14 The Prescriber Perspective Gifts Business courtesies Samples Key issues Nominal value? Patient benefit? Independent judgement?

S IDLEY A USTIN B ROWN & W OOD LLP 15 Compliance Are policies, procedures adequate for: Contracting Price reporting Recommending Acceptance of benefits from manufacturers

Paul E. Kalb, M.D., J.D. Sidley Austin Brown & Wood LLP DC1 #615905